Medical/Pharmaceuticals
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules
SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan He...
2026-06-24 15:07
8284
Milliken Expands Innovation Capabilities with New Polymer Solutions Pilot Plant in Pune, India
Facility strengthens ability to accelerate development and scale advanced materialsolutions for global markets. PUNE, India, June 24, 2026 /PRNewswire/ -- Milliken & Company has opened a new state of the art pilot plant facility in Pune, India, further strengthening its polymer solutions busine...
2026-06-24 14:24
6033
Cynosure Lutronic Spotlighted Structural Skin Tightening Innovation at IMCAS Asia 2026 in Bangkok
SINGAPORE, June 24, 2026 /PRNewswire/ -- Global medical aesthetics leader Cynosure Lutronic presented its latest non-invasive innovations at IMCAS Asia 2026 in Bangkok (19–21 June), featuring XERF™, a structural skin tightening treatment that focuses on comfort, safety, flexibility and no downtim...
2026-06-24 13:14
7577
Great Place To Work Reveals Southeast Asia's Best Workplaces™ in Healthcare & Biopharma
SINGAPORE, June 24, 2026 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, today announced the inaugural Southeast Asia's Best Workplaces™ in Healthcare & Biopharma 2026 list — a landmark recognition honouring 15 outstanding organizations that have set the benchmark...
2026-06-24 12:18
7043
Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
SHENZHEN, China, June 24, 2026 /PRNewswire/ -- From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center. Kexing Biopharm (688136.SH) showcased multiple self-developed innovative drug pipelines and over 30 products for international markets at the exhib...
2026-06-24 11:53
4699
Abu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership
ABU DHABI, UAE, June 24, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Biocom California, one of the world's largest life sciences associations representing more than 1,800 biotechnology, pharmaceutical and medical techno...
2026-06-24 07:11
6936
EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services
PROVIDENCE, R.I., June 23, 2026 /PRNewswire/ -- EpiVax, Inc., a recognized leader in immunogenicity risk assessment, announces the expansion of its laboratory facilities at its Providence, RI headquarters. The upgraded space has more than doubled the company's laboratory footprint, expanding the ...
2026-06-23 21:12
4507
Ambulatory Surgical Centres Poised for Sustained Growth as Healthcare Delivery Continues to Shift Beyond the Hospital
Frost & Sullivan identifies significant opportunities across ambulatory surgery, digital health, and connected care markets LONDON, June 23, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis highlights ambulatory surgical centres (ASCs) as one of the most significant growth opportunities r...
2026-06-23 20:17
5339
Fair Play Menarini International Award
Diego Milito and Emilio Butragueño among the winners of the 30th edition FLORENCE, Italy, June 23, 2026 /PRNewswire/ -- The list of winners of the 30th Fair Play Menarini International Award, scheduled forJuly 2 in Florence, continues to include great legends of world sport. Among the champions w...
2026-06-23 18:29
3086
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
* Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug ...
2026-06-23 18:10
7408
CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
SEOUL, South Korea, June 23, 2026 /PRNewswire/ -- Informa Markets Korea has
officially opened pre-registration for CPHI/ Hi Korea 2026, taking place at
COEX, Seoul, from August 25 to 27. Pre-registered visitors enjoy complimentary
entries.
2026-06-23 08:00
8557
DoH and Sanofi Partner to Advance Vaccine Innovation
ABU DHABI, UAE, June 23, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader, have signed an Memorandum of Understanding and intend to into an agreement to advance their partner...
2026-06-23 07:47
9938
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address ...
2026-06-23 05:37
8813
Texas A&M Study Highlights Pictor PictVet® as a Promising New Tool for Non-Invasive Beef Cattle Health Monitoring
Independent peer-reviewed research published in Frontiers in Veterinary Science reports strong assay performance in a proof-of-concept evaluation using bovine nasopharyngeal swab samples CARLSBAD, Calif., June 23, 2026 /PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic platform co...
2026-06-23 01:37
5041
Biomerics Appoints Kristin Mason as Chief Financial Officer
SALT LAKE CITY, June 22, 2026 /PRNewswire/ -- Biomerics, a leading vertically integrated contract manufacturer for the interventional medical device market, today announced the appointment of Kristin Mason as Chief Financial Officer. Mason joins Biomerics following an extensive career leading fin...
2026-06-22 22:03
5906
Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
* European approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progression-free sur...
2026-06-22 21:14
6133
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth
With advancing EBD rollout and steady injectables expansion, integrated treatment protocols deliver unique competitive edges for high-quality regional growth HONG KONG, June 22, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-...
2026-06-22 20:16
9526
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of sat...
2026-06-22 19:33
8694
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment ...
2026-06-22 14:00
8724
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
* ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors * K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China * Antengene r...
2026-06-22 08:30
7214
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 279 media titles]
2026-10-07 11:50Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 262 media titles]
2026-10-05 11:51Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24357